Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The TRIBE-2 study for colorectal cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 923

Dr Chiara Cremolini - Università di Pisa, Pisa, Italy

Dr Chiara Cremolini speaks to ecancer at the ESMO 2018 congress in Munich about the TRIBE-2 study for patients with metastatic colorectal cancer.

She outlines the design of the TRIBE-1 study, and how the TRIBE-2 study grew from this including the latest data.

Dr Cremolini outlines some of the adverse effects and how they can be clinically managed.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation